Register now to learn about a new option for relapsed or refractory follicular lymphoma

HER3-Targeting Antibody-Drug Conjugate Shows Encouraging Activity in Advanced Breast Cancer

Friday, December 28, 2018
U3-1402, an investigational antibody-drug conjugate (ADC) targeting HER3, induced objective response in more than 40% of heavily pretreated patients with HER3-expressing breast cancer, according to results presented at the 2018 San Antonio Breast Cancer Symposium.1

The objective response rate (ORR) was 42.9% (18/42), including 40% of patients treated at the 4 mg/kg dose and 60% of those treated at the 6.4 mg/kg dose. The median progression-free survival (PFS) was 8.3 months months (range, 1.2-15.8).

The overall disease control rate (DCR) was 90.5% (38/42). DCR was 86.7% at the 4 mg/kg dose and 100% at the 6.4 mg/kg dose.

The median time to response (TTR) was 2.6 months (range 1.4-2.8). Most responses proved to be durable, as the median duration of response (DOR) was not reached (range, 2.8-13.8 months) after a median follow-up of 10.5 months. Twenty-one patients remained on treatment as of the November 6 data cutoff.

In preliminary results from 21 patients presented at the 2018 ASCO Annual Meeting, the ORR was 33% and DCR was 95%.2“These results offer preliminary evidence of U3-1402 activity in HER3-positive metastatic breast cancer and further study is warranted,” lead author Norikazu Masuda, MD, PhD, National Hospital Organization, Osaka National Hospital, Osaka, Japan, said in a release. “The initial efficacy and safety data suggest that a HER3-targeting agent such as U3-1402 could provide a new treatment approach for patients with HER3-expressing metastatic breast cancer, who are in need of additional options to manage their disease.”

HER3 is overexpressed in breast cancer and several other types of tumors. U3-1402 consists of a fully human anti-HER3 antibody linked to a topoisomerase I inhibitor. To date, no HER3-targeted therapies have been approved.

Masuda and colleagues reported findings from an ongoing phase I/II trial (NCT02980341) to evaluate the safety, tolerability, and efficacy of U3-1402 in patients with HER3-overexpressiong metastatic breast cancer. The study comprises dose-escalation, dose-finding, and dose-expansion components.

Across the dose escalation and dose finding phases, 15 patients reeived the 4.8 mg/kg dose and 15 received the 6.4 mg/kg dose. The maximum tolerated dose was not reached during the dose-escalation part of the trial, and evaluation of those 2 doses continued in the dose finding part of the study.

The SABCS report represented an update of safety/tolerability and efficacy results. Investigator-assessed efficacy assessments included PFS, ORR, DCR, ORR, DCR, DOR, and TTR.

The data analysis included 42 patients who had a median age of 54.5 years. The cohort included 7 patients with HER2+ breast cancer, 21 with HR+/HER2- disease, 10 with triple-negative disease, and 4 with unknown molecular profile. The patients had received a median of 6 (range, 2-13) prior regimens, and 5 (range, 1-12) prior regimens for locally advanced/metastatic disease. More than 70% of the patients had liver and/or lung metastases, and 14.3% had brain/CNS metastases.

U3-1402 was generally well tolerated. Only 1 patient discontinued treatment because of treatment-emergent adverse events (TEAEs), and no fatal TEAEs occurred.

The safety analysis showed that 8 (19.0%) patients had TEAs requiring dose reduction, and 19 (45.2%) had TEAEs requiring dose interruption, most often neutropenia (23.8%), leukopenia (11.9%), and anemia and elevated liver AST (7.1% each).

Pulmonary AEs of special interest included 1 case each of grade 2 pneumonitis, grade 2 interstitial lung disease, grade 1 radiation fibrosis, and grade 3 radiation pneumonitis. The one patient who discontinued treatment because TEAEs did so because of grade 2 pneumonitis.

The most common (≥20%) all-grade AEs were nausea (85.7%), thrombocytopenia (71.4%), decreased appetite (66.7%), neutropenia (64.3%), leukopenia (59.5%), vomiting (54.8%), elevated liver enzymes (AST, 47.6%; ALT, 45.2%), anemia (38.1%), stomatitis (35.7%), diarrhea (31.0%), alopecia and fatigue (28.6% each), constipation (23.8%), and nasopharyngitis and malaise (21.4% each).

The most common (≥10%) grade ≥3 adverse events were thrombocytopenia (35.7%), neutropenia (28.6%), leukopenia (21.4%), anemia (16.7%), and elevated ALT (11.9%).

  1. Masuda N, Yonemori K, Takahashi S, et al. Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in HER3-overexpressing metastatic breast cancer: Updated results of a phase 1/2 trial. In: Proceedings from the 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. Abstract #PD1-03.
  2. Kogawa T, Yonemori K, Masuda N, et al. Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in breast cancer patients: Phase 1 dose escalation study. J Clin Oncol. 36, 2018 (suppl; abstr 2512).

This article originally appeared on OncLive® as “HER3-Targeting Antibody-Drug Conjugate Shows Encouraging Activity in Advanced Breast Cancer.”


Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
Related Articles
By: Carmante Extra, DNP, MSNEd, APRN, FNP-BC, and Mayra Lima, MSN, APRN, FNP-C
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
OncNurse Resources

Continuing Education
Web Exclusives

About Us
Advisory Board
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.